Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Female Contraception”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1985

Recent developments in female contraception: LHRH.

During the last few years new approaches to female contraception based on LHRH and its analogs have been developed. The physiological significance of pulsatile LHRH release and its stimulation of the pituitary has been elucidated by recent studies in rhesus monkey. Immunization against LHRH results in complete inhibition of reproductive function in animals and may find as a useful method of long-term fertility control in domestic animals. Clinical studies have utilized this knowledge to treat infertile hypogonadal women with chronic intermittent low-dose of LHRH. The superactive stimulatory LHRH analogs, used to treat infertility, paradoxically proved to have antifertility effects. They induce desensitization of the processes responsible for gonadotropic and gonadal hormone secretion, mediated by specific LHRH receptors in the pituitary and gonad. While contraceptive effectiveness of luteolytic approach remains to be proven, inhibition of ovulation by intranasal LHRH analog administration or continuous LHRH infusion by programmed minipumps seem to provide safe and effective contraception in women.

Amenorrhea↗
PubMed1991

Contraceptive female sterilization in Alabama: a replication of the WHO study.

The prevalence of female sterilization for contraceptive purposes has grown rapidly throughout the world, and is especially high in the United States. Yet the psychosocial impact of female sterilization is incompletely understood. Much of the previous research has been retrospective and has lacked comparison groups of women using other methods. Better designed, prospective studies have been needed, and the World Health Organization's Collaborative Prospective Study of Female Sterilization was conducted to address this need. No evidence was found in the WHO study of a significant impact of tubal ligation compared to other contraceptive methods on mental health, menstruation, or sexual satisfaction. The present study, a replication of the WHO study, compared 323 Alabama women undergoing elective contraceptive sterilization with 318 women using other techniques to control fertility. In general, the results supported the WHO study conclusions. Although sterilization produced a small increase in menstrual distress in Alabama, there were no significant differences between sterilization and comparison women in mental health or sexual satisfaction.

Adult↗
PubMed1985

Allosensitization in tumor therapy and prophylaxis, and in female contraception--a prospect for clinical use.

A hypothesis is presented on the possible role of allosensitization in therapy and prophylaxis of human tumors, and in human female contraception. The essence of the proposed treatment of human malignancies is allosensitization with allogeneic white blood cells by means of application of two blood transfusions from normal healthy donors within a certain time interval to patients with invasive or metastasizing cancer. The therapy should be accompanied by immunoglobulins, bacterial toxins and a single dose of cytostatics. In the case of a successful tumor regression a prophylaxis of recurrence should be made with two doses of intradermally injected allogeneic lympho-leucocytic concentrates mixed with bacterial toxins; such treatment might also be effective in tumor prophylaxis, or in long-lasting contraception in women. The hypothesis is supported by recent literature as well as by our recent results in the area of cell-mediated control of tissue proliferation, fetal allograft survival or tumor development. It is concluded that tumor rejection can be mediated not only by the direct effect of anti-tumor drugs but more effectively by the organisms mechanisms responsible for removal of undesirable tissue.

Blood Transfusion↗
PubMed1986

Interference in primate follicular maturation: an approach with inhibin for female contraception.

Investigations to study the effect of inhibin (purified from sheep ovaries) on the corpus luteum function of five regularly cycling bonnet monkeys were undertaken. The treatment with inhibin administered during the first three days of the cycle led to a delay in the occurrence of preovulatory estradiol peak; a reduction in the secretion of estradiol and progesterone during the cycle (significant in 2/5 cycles) and consistent reduction in the length of the luteal phase. There was no interference in the occurrence of physiological events of the cycle such as selection of dominant follicle, ovulation and corpus luteum formation. These results suggest that inhibin or one of its analogues, administered for a short time at the early part of the cycle, might prove useful as a female contraceptive.

Animals↗
PubMed1985

Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.

One hundred and one healthy regularly ovulating women used two superactive GnRH agonists, Buserelin and Nafarelin, for contraception for 3-26 months. The superagonists were administered once daily by a nasal spray. The treatment was initiated on one of the first 3 days of the menstrual cycle. Seventy-one volunteers used 200, 400 or 600 micrograms of Buserelin for contraception for 3-26 months. Normal ovulation was disturbed in all but 3 of 628 treatment months. No pregnancy occurred. Fifty-three women had regular or sparse menstrual-like bleedings during treatment while 18 developed amenorrhea. Normal ovulation and fertility rapidly returned after cessation of therapy. Thirty women received 125 or 250 micrograms of Nafarelin intranasally once daily for 3 months. The treatment consistently inhibited ovulation without serious side effects. The inhibition of ovulation by prolonged continuous intranasal GnRH agonist therapy is a promising new lead to peptide contraception in women.

Administration, Intranasal↗
PubMed1992

[Female contraception by a normal dose progestogen after 40 years of age. Possible association of nomegestrol--17-beta-estradiol acetate by percutaneous route].

Although fertility declines with age, the use of an effective contraceptive remains necessary in women over 40. Endocrine disorders, which are common in this age group, may also often require control. Conventional estroprogestogens, even those of the latest generation, cannot be used in women with a high cardiovascular risk, since age cannot be totally excluded as a possible risk factor. The contraceptive use of derivatives of 17-hydroxyprogesterone and 19-norprogesterone offer a promising alternative, despite the absence of any exhaustive investigation particularly in situations in which the blood level of estradiol has to be reduced. There are, however, some women who respond to this type of contraception by menstrual cycle irregularities, and sometimes by low blood levels of estradiol, regardless of the drug used. A preliminary study is described in which 5 mg of nomegestrol acetate was combined with 17-beta-estradiol by transcutaneous route and which has so-far demonstrated sustained contraceptive efficacy as well as excellent clinical and metabolic safety.

Administration, Cutaneous↗
PubMed1986

Potential application of inhibin in male and female contraception.

After a review of investigations into the possible use of inhibin in the regulation of male and female fertility, briefly described and summarized in this article, the authors conclude that, at least in experimental animals, inhibin causes a significant reduction in testicular and epididymal spermatozoa in the male and luteal phase defect in the female. The precise mechanism by which inhibin brings about these effects is not known at present, and its elucidation will greatly help in the more effective use of inhibin.

Animals↗
PubMedDate not supplied

Chlamydial salpingitis in female guinea pigs receiving oral contraceptives.

Female guinea pigs were given daily doses of a combination of oral contraceptive (OC) agents, consisting of mestranol and norethynodrel suspended in sesame oil or distilled H2O, and were infected in the genital tract with the chlamydial agent of guinea pig inclusion conjunctivitis (GPIC). Counts of chlamydial inclusions in cells of vaginal smears collected during infection, showed prolongation and enhancement of infection in OC-treated animals as compared with controls. Appearance of IgG and IgA antibodies to GPIC in genital secretions, as determined by enzyme-linked immunosorbent assay (ELISA), was also delayed in OC-treated animals as compared with controls. OC-treated infected animals were killed on days 15 and 43, and gross pathological evidence for ascending infection culminating in salpingitis was found in all of five and four of five animals, respectively. On the other hand, among untreated infected controls on each sacrifice day, only one of five animals had any evidence for ascending infection. Chlamydiae were detected by light and electron microscopy in fallopian tube tissue collected on day 15 following OC-treatment but not in tissue from control animals.

Animals↗
PubMed1986

[Contraception in female adolescents. Point of view of a pediatrician].

Sexual relationships appear to begin earlier nowadays, but sexual intercourse is in fact fairly infrequent and so permanent contraception may not be required, even though it is the most effective method, and this is the aim. The author concludes that there is no "best choice", but that in each case one has to try to use what is "least undesirable".

Adolescent↗